Versant Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Versant Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-10,265	Closed	-$348K	–	2869
2026 Q2	$348K	Buy	10,265 +1,399	+16%	+$46.6K	0.03%	421
2026 Q1	$267K	Buy	8,866 +1,932	+28%	+$62.2K	0.03%	483
2025 Q4	$216K	Buy	6,934 +1,374	+25%	+$33.8K	0.03%	465
2025 Q3	$112K	Buy	5,560 +981	+21%	+$17.2K	0.02%	668
2025 Q2	$76.7K	Sell	4,579 -718	-14%	-$11.6K	0.01%	786
2025 Q1	$81.4K	Buy	5,297 +4,312	+438%	+$77K	0.01%	697
2024 Q4	$21.7K	Buy	985 +760	+338%	+$13.8K	﹤0.01%	987
2024 Q3	$4.05K	Buy	+225	New	+$3.94K	﹤0.01%	1360

Other funds holding TEVA

WWM

Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

CAM

Cacti Asset Management Atlanta, Georgia $1.89B AUM 58.55% 1-Year Est. Return

IRC

Investors Research Corp Atlanta, Georgia $569M AUM 15.41% 1-Year Est. Return

VEM

Vann Equity Management Plano, Texas $168M AUM

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GWM

Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return

BAM

Byrne Asset Management Kingston, New Jersey $179M AUM 29.67% 1-Year Est. Return

EWP

Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return

AAG

Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

Versant Capital Management's TEVA Position: Q3 2026 in Review

Versant Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2026, closing a stake of 10,265 shares — an estimated $348K sold.

Versant Capital Management first reported a position in TEVA in Q3 2024 and held it in 8 quarters. The position peaked at $348K in Q2 2026. 10 funds tracked by Wall St. Rank hold TEVA as of Q3 2026.

Versant Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2026 after selling out during the quarter.
Versant Capital Management sold 10,265 Teva Pharmaceutical Industries Limited shares in Q3 2026, an estimated $348K.
Versant Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q3 2024 and held it in 8 quarters.
Versant Capital Management's Teva Pharmaceutical Industries Limited position peaked at $348K in Q2 2026.
10 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.